Submitted:
10 October 2025
Posted:
11 October 2025
You are already at the latest version
Abstract
Keywords:
- (a)
- quantify the regular and unexpected out-of-pocket expenditures;
- (b)
- explore the impact of caregiving demands on maternal employment and household resilience;
- (c)
- assess the HRQoL in children with DMD using validated tools; and
- (d)
- evaluate how clinical and socioeconomic variables (e.g., allowance status, mobility, regional disparities) shape HRQoL outcomes.
2. Materials and Methods
2.1. Study Design and Patient Population
2.2. Measures
2.3. Statistical Analysis
3. Results
3.1. Socio-Demographic and Clinical Characteristics
3.2. Household Financial Burden in Relation to Income and Allowance Status
3.2.1. Overall Financial Burden
3.2.2. Impact of Caregiving on Maternal Employment
3.3. Health-Related Quality of Life Outcomes
3.3.1. Quality of Life Compared to Healthy Peers
3.4. Associations Between Socioeconomic and Clinical Variables and HRQoL domains
4. Discussion
5. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ryder, S.; Leadley, RM.; Armstrong, N.; Westwood, M.; De Kock, S.; Butt, T.; Jai, M.; Kleijnen, J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. Orphanet J of Rare Dis, 2017, 12, 1–20. [Google Scholar] [CrossRef]
- Messina, S.; Vita, GL. ; Clinical management of Duchenne muscular dystrophy: the state of the art. Neurol Sci, 2018, 39, 1837–45. [Google Scholar] [CrossRef]
- Crisafulli, S.; Sultana, J.; Fontana, A.; Salvo, F.; Messina, S.; Messina, S.; Trifiro, G. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet J of Rare Dis, 2020, 15, 1–20. [Google Scholar]
- Thongsing, A.; Likasitwattanakul, S.; Sanmaneechai, O. Reliability and validity of the Thai version of the Pediatric Quality of Life inventoryTM 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy. Health Qual Life Outcomes, 2019, 17, 1–8. [Google Scholar] [CrossRef]
- Birnkrant, DJ.; Bushby, K.; Bann, CM.; Apkon, SD.; Blackwell, A.; Brumbaugh, D.; Case, L.; Clemens, P.; Hadjigiannakis, S.; Pandya, S.; et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol, 2018, 17, 251–67. [Google Scholar] [CrossRef]
- Birnkrant, DJ.; Bushby, K.; Bann, CM.; Alman, BA.; Apkon, SD.; Blackwell, A.; Case, L.; Cripe, L.; Hadjigiannakis, S.; Olson, A.; et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol, 2018, 17, 347–61. [Google Scholar]
- Birnkrant, DJ.; Bushby, K.; Bann, CM.; Apkon, SD.; Blackwell, A.; Colvin, M.; Cripe, L.; Herron, A.; Kennedy, A.; Kinnet, K.; et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 2018, 17, 445-55. [Google Scholar] [CrossRef] [PubMed]
- Angelini, C.; Peterle, E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol, 2012, 31, 9–15. [Google Scholar] [PubMed]
- Takeda, S.; Clemens, PR.; Hoffman, EP. Exon-Skipping in Duchenne Muscular Dystrophy. J Neuromuscul Dis, 2021, 8, 343–58. [Google Scholar] [CrossRef] [PubMed]
- Markati, T.; Oskoui, M.; Farrar, MA.; Duong, T.; Goemans, N.; Servais, L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol 2022, 21, 814-29. [Google Scholar] [CrossRef]
- Iftikhar, M.; Frey, J.; Shohan, MJ.; Malek, S.; Mousa, SA. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther 2021, 220. [Google Scholar] [CrossRef]
- Sun, C.; Shen, L.; Zhang, Z.; Xie, X. Therapeutic strategies for duchenne muscular dystrophy: An update. Genes, 2020, 11, 1–25. [Google Scholar] [CrossRef]
- Butterfield, RJ.; Kirkov, S.; Conway, KM.; Johnson, N.; Matthews, D.; Phan, H.; Cai, B.; Paramsothy, P.; Thomas, S.; Feldkamp, M. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle Nerve, 2022, 66, 15–23. [Google Scholar] [CrossRef]
- Shieh, PB.; McIntosh, J.; Jin, F.; Souza, M.; Elfring, G.; Narayanan, S.; Thrifillis, P.; Peltz, S.; McDonald, C.; Darras, B.; et al. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A Post Hoc analysis from the ACT DMD trial. Muscle Nerve, 2018, 58, 639–45. [Google Scholar] [CrossRef] [PubMed]
- Landfeldt, E.; Edström, J.; Buccella, F.; Kirschner, J.; Lochmüller, H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol., 2018, 60, 987–96. [Google Scholar] [CrossRef] [PubMed]
- Wahlgren, L.; Kroksmark, AK.; Tulinius, M.; Sofou, K. One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. Eur J Epidemiol, 2022, 37, 147–56. [Google Scholar] [CrossRef] [PubMed]
- Broomfield, J.; Hill, M.; Guglieri, M.; Crowther, M.; Abrams, K. Life expectancy in Duchenne muscular dystrophy. Neurology, 2021, 97, 304–14. [Google Scholar] [CrossRef]
- Eu, WH.; Busse, R.; Klazinga, N.; Panteli, D.; Quentin, W. The editors Improving healthcare quality in Europe Characteristics, effectiveness and implementation of different strategies. Health Policy Series, 2019, 53, 4–30. [Google Scholar]
- European Commission. The European Health Union: acting together for people’s health COM (2024) 206 final. Available online: https://health.ec.europa.eu/publications/communication-european-health-union_en#details (accessed on 28 June 2025).
- Whittal, A.; Meregaglia, M.; Nicod, E. The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. Patient, 2021, 24, 485–503. [Google Scholar] [CrossRef]
- Brettschneider, C.; Luhmann, D.; Raspe, H. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). Health Technol Assess, 2011, 7, 1–15. [Google Scholar]
- Kyte, D.; Duffy, H.; Fletcher, B.; Gheorghe, A.; Mercieca-Bebber, R.; King, M.; Draper, H.; Ives, J.; Brundage, M.; Blazeby, J.; et al. Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. J Am Med Assoc, 2014, 319, 483–494. [Google Scholar] [CrossRef] [PubMed]
- Trigg, A.; Howells, R. Patient-Reported Outcomes within Health Technology Assessment Decision Making: Current Status and Implications for Future Policy. Value Health 2015, 18, A 739. [Google Scholar] [CrossRef]
- Cavazza, M.; Kodra, Y.; Armeni, P.; De Santis, M.; López-Bastida, J.; Linertová, R.; Oliva-Moreno, J.; Serano-Aguilar, P.; Posata-de la Paz, M.; Taruscio, D. , et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. European J Health Econ, 2016, 17, 19–29. [Google Scholar]
- Teoh, LJ.; Geelhoed, EA.; Bayley, K.; Leonard, H.; Laing, NG. Health care utilization and costs for children and adults with duchenne muscular dystrophy. Muscle Nerve, 2016, 53, 877–84. [Google Scholar] [CrossRef] [PubMed]
- Thayer, S.; Bell, C.; McDonald, C. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States. J Manag Care Spec Pharm, 2017, 23, 633–641. [Google Scholar] [CrossRef]
- Schreiber-Katz, O.; Klug, C.; Thiele, S.; Schorling, E.; Zowe, J.; Reilich, P.; Nageis, K.; Walter, M. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014, 9, 1–13. [Google Scholar] [CrossRef]
- Larkindale, J.; Yang, W.; Hogan, PF.; Simon, CJ.; Zhang, Y.; Jain, A.; Habeeb-Louks, E.; Kennedy, A.; Cwik, V. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve, 2014, 49, 431–8. [Google Scholar] [CrossRef]
- Shehata, Z.; Rabea, H.; El Sherif, R.; Abdelrahim, M.; Dawoud, D. Estimating Societal Cost of Illness and Patients’ Quality of Life of Duchenne Muscular Dystrophy in Egypt. Value Health Reg Issues, 2023, 33, 10–16. [Google Scholar]
- Flores, D.; Ribate, M.; Montolio, M.; Ramos, F.; Gómez, M.; García, C. Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain. European J Health Econ, 2020, 7, 1015–1023. [Google Scholar] [CrossRef]
- Labisa, P.; Andreozzi, V.; Mota, M.; Monteiro, S.; Alves, R.; Almeida, J.; Vandewalle, B.; Felix, J.; Buesch, K.; Canhão, H.; et al. Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study. PharmacoEconomics, 2022, 6, 211–218. [Google Scholar] [CrossRef]
- Orso, M.; Migliore, A.; Polistena, B.; Russo, E.; Gatto, F.; Monterubbianesi, M.; d’Angela, D.; Spandonaro, F.; Pane, M. Duchenne muscular dystrophy in Italy: A systematic review of epidemiology, quality of life, treatment adherence, and economic impact. PLos One, 2023, 18, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Rudolfsen, J.; Vissingb, J.; Werlauffc, U.; Olesend, C.; Illume, N.; Olsena, J.; Bo Poulsenf, P.; Strandg, M.; Bornh, A. Burden of Disease of Duchenne Muscular Dystrophy in Denmark – A National Register-Based Study of Individuals with Duchenne Muscular Dystrophy and their Closest Relatives. J Neuromusc Dis, 2024, 11, 443–457. [Google Scholar] [CrossRef]
- Mori-Yoshimura, M.; Ishigaki, K.; Shimizu-Motohashi, Y.; Ishihara, N.; Unuma, A.; Yoshida, S.; Nakamura, H. Social difficulties and care burden of adult Duchenne muscular dystrophy in Japan: a questionnaire survey based on the Japanese Registry of Muscular Dystrophy (Remudy). Orphanet J Rare Dis, 2024, 19, 182–192. [Google Scholar] [CrossRef]
- Schwartz, C.; Stark, R.; Audhya, I.; Gooch, K. Characterizing the quality-of-life impact of Duchenne muscular dystrophy on caregivers: a case-control investigation. J Patient Rep Outcomes, 2021, 5, 124–140. [Google Scholar] [CrossRef]
- Sirari, T.; Renu Suthar, R.; Kansra, P.; Singh, A.; Prinja, S.; Malviya, m.; Chauhan, A.; Viswanathan, V.; Gupta, V.; Sankhayan, N. Socioeconomic determinants of the quality of life in boys suffering from Duchenne muscular dystrophy & their caregivers. Indian J Med Res, 2025, 161, 215–225. [Google Scholar]
- Uttley, L.; Carlton, J.; Buckley Woods, H.; Brazier, J. A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes, 2018, 16, 237–252. [Google Scholar] [CrossRef] [PubMed]
- Gkoltsiou, K.; Dimitrakaki, C.; Tzavara, C.; Papaevangelou, V.; Varni, JW.; Tountas, Y. Measuring health-related quality of life in Greek children: Psychometric properties of the Greek version of the Pediatric Quality of Life Inventory TM 4.0 Generic Core Scales. Qual Life Res 2008, 17, 299–305. [Google Scholar] [CrossRef] [PubMed]
- Katsomiti, E.; Kastanioti, C.; Chroni, E.; Mavridoglou. G. Reliability and validity of the Greek version of the Pediatric Quality of Life InventoryTM 3.0 Duchenne Muscular Dystrophy module in children with Duchenne muscular dystrophy. Paliat Med Pract, 2025, 20, 1–12. [Google Scholar]
- Angelis, A.; Tordrup, D.; Kanavos, P. Socio-economic burden of rare diseases: A systematic reviewof cost of illness evidence. Health Policy, 2015, 119, 964–979. [Google Scholar] [CrossRef]
- Valentin Brodszky, V.; Beretzky, Z.; Baji, P.; Rencz, F.; Péntek, M.; Rotar, A.; Tachkov, K.; Mayer, S.; Judit Simon, J.; Niewada, M.; Hren, R.; Gulácsi, L. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Economics, 2019, 20, 155–172. [Google Scholar] [CrossRef]
- García-Pérez, L.; Linertová, R.; Valcárcel-Nazco, C.; Posada, M.; Gorostiza, I.; Serrano-Aguilar, P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis, 2021, 16, 178–189. [Google Scholar] [CrossRef]
- Jo, C. Cost-of-illness studies: concepts, scopes, and methods. Clin Molec Hepatology, 2014, 20, 327–337. [Google Scholar] [CrossRef]
- Conway, K.; Grosse, S.; Ouyang, L.; Street, N.; Romitti, P. Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state. Muscle Nerve, 2022, 65, 574–580. [Google Scholar] [CrossRef]
- Varni, JW.; Seid, M.; Burwinkle, T.; Skarr, D. The PedsQLTM 4. 0 as a pediatric population health measure: Feasibility, Reliability and Validity Ambul Pediatr, 2003, 3, 329–41. [Google Scholar]
- Gocheva, V.; Schmidt, S.; Orsini, AL.; Hafner, P.; Schaedelin, S.; Rueedi, N.; Weber, P.; Fischer, D. Association Between Health-Related Quality of Life and Motor Function in Ambulant and Nonambulant Duchenne Muscular Dystrophy Patients. J Child Neurol, 2019, 34, 873–885. [Google Scholar] [CrossRef]
- Liang, R.; Chan, SHS. ; Ho, FKW.; Tang, OC.; Cherk, SWW.; Ip, P.; Ying Lau, EY. Health-related quality of life in Chinese boys with Duchenne muscular dystrophy and their families. J Child Health Care, 2019, 23, 495–506. [Google Scholar] [CrossRef]
- Uzark, K.; King, E.; Cripe, L.; Spicer, R.; Sage, J.; Kinnett, K.; Wong, B.; Pratt, J.; Varni, J. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics, 2012, 130, 1559–66. [Google Scholar] [CrossRef] [PubMed]
- Davis, SE.; Hynan, LS.; Limbers, CA.; Andersen, CM.; Greene, MC.; Varni, JW.; Iannaccone, S. The PedsQLTM in Pediatric Patients with Duchenne Muscular Dystrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. J Clin Neuromusc dis 2010, 11, 97–109. [Google Scholar] [CrossRef] [PubMed]
- Bray, P.; Bundy, AC.; Ryan, MM.; North, KN.; Everett, A. Health-related quality of life in boys with duchenne muscular dystrophy: Agreement between parents and their sons. J Child Neurol, 2010, 25, 1188–94. [Google Scholar] [CrossRef]
- Hanania, JW.; George, JE.; Rizzo, C.; Manjourides, J.; Goldstein, L. Agreement between child self-report and parent-proxy report for functioning in pediatric chronic pain. J Patient Rep Outcomes, 2024, 8, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Rajmil, L.; López, AR.; López-Aguilà, S.; Alonso, J. Parent-child agreement on health-related quality of life (HRQOL): A longitudinal study. Health Qual Life Outcomes, 2013, 11, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Otto, C.; Steffensen, BF.; Højberg, AL.; Barkmann, C.; Rahbek, J.; Ravens-Sieberer, U.; Mahoney, A.; Vry, J.; Gramsch, K.; Thompson, R.; et al. Predictors of Health-Related Quality of Life in boys with Duchenne muscular dystrophy from six European countries. J Neurol. 2017, 264, 709–23. [Google Scholar] [CrossRef] [PubMed]
- Wei, Y.; Speechley, KN.; Zou, G.; Campbell, C. Factors Associated with Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy. J Child Neurol, 2016, 31, 879–86. [Google Scholar] [CrossRef] [PubMed]



| Variable | Mean | SD | Range |
| Age at onset (years) | 3.58 | 2.83 | 0-10 |
| Age at time of the evaluation (years) | 12.52 | 2.97 | 8-19 |
| Variable | N | % | |
| Age distribution(years) | |||
| 5-7 | 9 | 18.0% | |
| 8-12 | 24 | 48.0% | |
| 13-18 | 17 | 34.0% | |
| Total | 50 | 100% | |
| Non-ambulatory patients | 15 | 30.0% | |
| Current steroid use | 23 | 46.0% | |
| Physiotherapy | 27 | 54.0% | |
| Family history | 34 | 68.0% |
| 5-7 (years) | 8-12 (years) | 13-18 (years) | ||||
| Mean | SD | Mean | SD | Mean | SD | |
| Child self-report | (Ν=14) | (Ν=11) | ||||
| Total Score GC | 59.86 | 15.10 | 61.65 | 18.47 | ||
| Physical Health Summary Score | 46.21 | 25.04 | 39.77 | 29.42 | ||
| Emotional Score | 67.14 | 15.65 | 72.39 | 17.68 | ||
| Social Score | 66.79 | 14.22 | 71.82 | 17.65 | ||
| School Score | 67.50 | 19.19 | 76.70 | 17.59 | ||
| Phychosocial Score | 67.14 | 12.06 | 73.64 | 14.66 | ||
| Parent proxy report | (Ν=7) | (Ν=20) | (Ν=15) | |||
| Total Score GC | 65.83 | 20.94 | 60.82 | 16.90 | 49.47 | 20.42 |
| Physical Health Summary Score | 30.77 | 48.44 | 26.41 | 25.22 | 29.15 | |
| Emotional Score | 75.00 | 21.41 | 69.25 | 18.23 | 64.64 | 27.42 |
| Social Score | 64.11 | 20.70 | 62.00 | 23.92 | 56.61 | 17.64 |
| School Score | 71.43 | 19.30 | 71.00 | 17.74 | 75.23 | 19.12 |
| Phychosocial Score | 70.22 | 19.01 | 67.42 | 15.75 | 64.83 | 19.53 |
| 5-7 (years) | 8-12 (years) | 13-18 (years) | All | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Child self-report | (Ν=18) | (Ν=13) | (Ν=31) | |||||
| Total (18) | 70.85 | 11.55 | 71.02 | 22.92 | 70.92 | 16.91 | ||
| Daily Activities (5) | 74.44 | 16.71 | 67.69 | 29.41 | 71.61 | 22.71 | ||
| Treatment Barriers (4) |
75.46 | 21.63 | 71.35 | 22.69 | 73.82 | 21.77 | ||
| Worry (6) | 66.69 | 17.56 | 77.63 | 15.17 | 71.28 | 17.23 | ||
| Communication (3) | 66.67 | 21.77 | 63.46 | 38.12 | 65.32 | 29.19 | ||
| Parent proxy report | (Ν=8) | (Ν=24) | (Ν=16) | (Ν=48) | ||||
| Total (18) | 76.18 | 20.69 | 66.21 | 18.73 | 56.74 | 25.62 | 64.71 | 22.14 |
| Daily Activities (5) | 56.88 | 33.16 | 60.83 | 25.62 | 50.00 | 38.21 | 56.56 | 31.22 |
| Treatment Barriers (4) |
82.81 | 21.84 | 71.20 | 20.62 | 63.28 | 32.02 | 70.48 | 25.59 |
| Worry (6) | 84.38 | 19.13 | 64.90 | 20.79 | 56.04 | 28.49 | 65.19 | 24.82 |
| Communication (3) | 84.38 | 16.33 | 69.10 | 30.74 | 59.90 | 36.80 | 68.58 | 31.66 |
| Daily activities |
Treat- ment |
Worry |
Commu- nication |
Total Score DMD | Total Score GC | Physical Health Summary Score | Emotional Score |
Social Score |
|
| Treatment | 0.570** | ||||||||
| Worry | 0.551** | 0.466** | |||||||
| Commu- nication |
0.543** | 0.353** | 0.465** | ||||||
| Total Score DMD | 0.881** | 0.747** | 0.772** | 0.719** | |||||
| Total Score GC | 0.760** | 0.582** | 0.672** | 0.414** | 0.782** | ||||
| Physical Health Summary Score | 0.747** | 0.436** | 0.570** | 0.376** | 0.690** | 0.825** | |||
| Emotional Score | 0.415** | 0.266* | 0.595** | 0.224 | 0.494** | 0.653** | 0.420** | ||
| Social Score | 0.696** | 0.544** | 0.662** | 0.420** | 0.739** | 0.837** | 0.570** | 0.521** | |
| School Score | 0.437** | 0.533** | 0.440** | 0.429** | 0.564** | 0.567** | 0.145 | 0.374** | 0.603** |
| **. Correlation is significant at the 0.01 level (2-tailed). | |||||||||
| *. Correlation is significant at the 0.05 level (2-tailed). | |||||||||
| x/y | Allowance* |
Annual Unexpected Expenses ** |
Provison by Insurance** | Monthly expenses** | Use of Wheelchair** | Age Group* | Corticoids** |
| Daily activities | Yes | Yes | Yes | ||||
| Treatment | Yes | Yes | |||||
| Worry | Yes | Yes | Yes | Yes | Yes | ||
| Communication | Yes | ||||||
| Total Score DMD | Yes | ||||||
| Physical Health Summary Score | Yes | Yes | Yes | Yes | |||
| Emotional Score | Yes | Yes | Yes | ||||
| Social Score | Yes | ||||||
| School Score | Yes | ||||||
| Phychosocial Score | Yes | Yes | |||||
| Total Score GC | Yes | Yes | Yes | Yes | |||
| *Kruskal–Wallis test was applied for categorical variables with >2 groups (e.g., age groups, allowance status, region). **Mann–Whitney U test was applied for dichotomous variables (e.g., wheelchair use, corticosteroid treatment, insurance status) | |||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).